Michael B. Atkins, MD, reviews a case involving a female patient who was diagnosed with stage IV BRAF-mutated melanoma, and shares insights on the patient’s prognosis and his approach to diagnosis.
A 62-Year-Old Female with Stage IV BRAF-Mutated Melanoma
Michael B Atkins, MD, shares insights on the prognosis of patient’s diagnosed with advanced melanoma and discusses the value of BRAF mutation testing.
An overview of treatments for metastatic melanoma, including data updates regarding combination options.
Dr Atkins shares his approach to first-line treatment and reviews data regarding treatment sequencing from the DREAMseq Trial.
An expert perspective on how to best treat a patient diagnosed with stage IV BRAF-mutated melanoma.
Immune-related adverse events are often a sign treatment is working. Dr Atkins discusses potential adverse events and how he counsels patients about them.
Insights about second-line treatment options for metastatic melanoma and discusses available data for treatment sequencing.
Dr Atkins discusses current unmet needs in the treatment landscape for metastatic melanoma and provides an overview of some of the treatments currently under investigation that show promise.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
